meta|evidence oncology

Living systematic review and meta-analysis

limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M) 1
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)

immune chekpoint inhibitors
Immune checkpoint association
nivolumab plus ipilimumab

versus all
vs non active control
vs no additional treatment

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -